Objectives: Hemophilia is a hereditary, lifelong bleeding disorder. Patients are deficient in either coagulation factor VIII (hemophilia A) or IX (hemophilia B). This study is aimed to assess the economic impact of these conditions in Mexico. MethOds: In this cost-of-illness study, both direct medical costs (diagnosis, follow-up, prophylaxis and on-demand coagulation factor replacement therapy, inpatient and outpatient care of hemorrhages and complications) and indirect costs related with loss of productivity in either adult patients or in parents of affected children along one year were assessed. Local demographic and epidemiological data (last update: 2011), as well as annual bleeding rates in both prophylaxis and on-demand approaches were extracted from published sources. Resource use patterns were derived mainly from Mexican Clinical Practice Guidelines co-authors (n= 8) through a survey. Unitary costs of medical resources were gathered mainly from Instituto Mexicano del Seguro Social (IMSS) sources. It is assumed that productivity losses of adult patients/parents of hemophiliac children are proportional to the number of days in hospital; average per hour wage and worked hours per week were extracted from National Statistics Office database. All costs are expressed in 2013 USD. Results: A total of 3906 (87%) type A and 597 (13%) type B patients comprised the 2011 documented prevalence of hemophilia in Mexico. Most (57%) of all patients received medical care at IMSS. Direct medical costs (79.3 USD millions) and indirect costs (370,398 USD) accounted for 99.5% and 0.5% of total costs (79.7 USD millions), respectively. Among direct medical costs, acquisition of coagulation factors represented the most important category (55.1 USD millions, 69.23%), followed by non-pharmacological care of hemorrhages (20 USD million, 25.12%). Average cost per patient was very similar: 18,152 and 14,662 USD for type A and B, respectively. cOnclusiOns: Despite its low prevalence, hemophilia imposes a considerably high economic burden in Mexico´s health care system.
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PSY23 mediCal aNd eCoNomiC imPaCT of iNfaNTile haemaNgioma iN fraNCe PreviouS To ProPraNolol uSe

Taieb C CrééS, Paris, France
Objectives: : Estimate the cost of treatment of IH previous to introduction of propranolol in the treatment of haemangioma; Infantile haemangioma is a common lesion affecting around 10% of children. At least 30% of haemangiomas require treatment. MethOds: Observational multicentric retrospective study at five expert centres treating children with haemangioma. The first 10 patient records, from each centre, of patients having been diagnosed, between the age of one and five months before 31/12/2007, with a haemangioma measuring > 1.5 cm in diameter, having already received corticosteroid treatment, were identified and selected. Results: 53 children were included. Haemangioma was mixed (cutaneous and subcutaneous) in 69.0% of children, and was located on the head and neck in 88.7% of cases. Complications arose in 75.5% of children. 83.0% of the children underwent additional tests in view of diagnosis and treatment of haemangioma. Tests most often included an MRI-scan (39.6%), an ophthalmological examination (30.2%) or heart ultrasound (32.1%). A dermatologist followed the patients in 71.7% of cases. 69.8% of the children were admitted to hospital at least once for their haemangioma and 17.0% had laser treatment. The average cost of treatment (according to the health insurance fund) of children with haemangioma was high, reaching € 6,407.00 on average. The highest expenditure item was hospitalisation at an average cost of € 5,337.00 (equivalent to 83% of the total average cost). cOnclusiOns: IH has a significant medical and financial impact, requiring relatively heavy medical treatment (numerous medical consultations with various specialists, frequent additional tests, long-term medication and surgery and laser treatment), the impact being even more significant the more serious the haemangioma. Introduction of propranolol in the treatment of IH should reduce treatment costs appreciably, notably by reducing the length of the hospital stays.
PSY24
CoST of iNTraveNeouS PaTieNT-CoNTrolled aNalgeSia (iv PCa) equiPmeNT aNd oPioid mediCaTioN for orThoPediC aNd aBdomiNal SurgerieS iN uNiTed STaTeS hoSPiTalS
Ji X 1 , Stephens JM 1 , Palmer P 2 1 Pharmerit International, Bethesda, MD, USA, 2 AcelRx Pharmaceuticals, Redwood City, CA, USA Objectives: IV PCA equipment and opioid cost analyses on specific procedures are lacking. This study estimates the IV PCA hospital cost for the first 48 postoperative hours for 3 inpatient surgeries. MethOds: Descriptive analyses using the Premier database (2010~2012) of > 500 US hospitals were conducted on cost of IV PCA after total knee or hip arthroplasty (TKA or THA) or open abdominal surgeries. Weighted average cost of each component was aggregated for total costs. Direct acquisition and indirect cost (labor, pharmacy, etc.) were included. Results: Of 11,805,513 patients, 272,443 (2.3%), 139,275 (1.2%) and 195,062 (1.7%) patients had TKA, THA and abdominal surgeries, respectively, with 20% of TKA and abdominal and 23% THA patients having specific IV PCA charges. Morphine (57%) and hydromorphone (44%) were the most frequently used PCA drugs, with the mean cost per 30 cc syringe of $16 (30 mg) and $21 (6 mg), respectively. Number of syringes for morphine and hydromorphone were 1.9 and 3.2 (TKA), 2.0 and 4.2 (THA), 2.5 and 3.9 (abdominal). Average costs of PCA pump, IV tubing set and drug ranged from $46 to $48, $20 to $22 and $33 to $46, respectively. Pump, tubing and saline required to maintain patency of IV PCA catheter over 48 hours ranged from $9 to $13, $8 to $9, and $20 to $22, respectively. Supplemental opioids during IV PCA use ranged from a low of $56 for THA to $87 for abdominal surgeries. Aggregated mean IV PCA/opioid total costs per patient were $196 (THA), $203 (TKA) and $243 (abdominal surgeries). cOnclusiOns: Although IV PCA is a 40-year old technology, the cost of equipment and opioid drugs in these postoperative patients is
PSY19 aN eCoNomiC evaluaTioN of differeNT ProCedureS iN BariaTriC SurgerY
Bellelli S 1 , Armeni P 2 , Tarricone R 2 , Turchetti G 1 1 Scuola Superiore Sant'Anna, Pisa, Italy, 2 Bocconi University, Milano, Italy Objectives: The aim of this study was to estimate the social cost of the three main bariatric surgery techniques used for the treatment of morbid obesity: gastric banding (GB), gastric by-pass (GBP), and sleeve gastrectomy (SG). MethOds: The study was designed as longitudinal multicenter survey. Adult patients in charge to 6 Hospital Centers in Italy have been enrolled at the time of the intervention and followed up to 1 year. Direct medical costs have been estimated using tariffs for laboratory tests, diagnostic exams, visits, and prices for drugs. Inpatient cost data have been collected at the Center level, as well as the costs of intervention. Non medical costs included costs for travel and accommodation, domestic help and informal care. The loss of productivity of patients have been estimated using the human capital approach. Costs are reported as mean (± standard deviation) in Euro 2013. Results: 301 patients have been enrolled and 1 year after the intervention a BMI reduction of 19%, 35% and 29% have been observed for GB, GBP and SG respectively. The social cost of the intervention amounted to € 6,853 (± € 1,328) for GB, € 9,934 (± € 3,370) for GBP and € 8,840 (± € 1,766) for SG. The social annual cost in the year after the intervention has been estimated as € 2,421 (± € 2,036) for GB (of these 31% were direct non medical costs and 36% were indirect costs), € 3,019 (± € 2,428) for GBP (of these 43% were direct non medical costs and 22% were indirect costs) and € 2,518 (± € 2.083) for SG (of these 43% were direct non medical costs and 24% were indirect costs). cOnclusiOns: As compared to GB and SG, GBP was most effective with higher costs of intervention and follow up.
PSY20
CoST aNalYSiS of imPlemeNTiNg exPaNded umBiliCal Cord Blood grafT iN CaNada
Tremblay G 1 , Cohen S 2 , Roy J 2 1 Adelphi Values, Boston, MA, USA, Montreal, QC, Canada Objectives: Umbilical cord blood graft (CBG) is an option for hematopoietic stem cell transplantation (HSCT) where bone marrow or peripheral stem-cell transplant (BM/PB) is not possible. Compared to traditional CBG, expanded CBG (ECBG) improves survival and clinical outcomes including median times to platelet and absolute neutrophil count engraftment, chronic and acute graft-versus-host disease (GvHD) and relapse rate. We assessed the costs and cost-effectiveness from the societal perspective of implementing ECBG in Canada. MethOds: Economic and epidemiologic models were developed using the results of a literature review and hospital data analysis, and included direct and indirect costs (e.g. productivity costs). We compared (1) BM/PB with unrelated donors (UD), (2) double umbilical cord blood graft (DUCB), (3) expanded umbilical cord blood graft (EUCB) with one or two cords (optimistic and conservative scenarios) in patients without an option for matched-related donors. Results: Total treatment (direct) costs comprised bone marrow and cord procurement (18-36%), donor search (16-19%), hospitalization (14-18%), and pharmacy (10-14%). DUCB costs were the highest of the different options, totalling $210,000, followed by EUCB (conservative; $206,000, optimistic; $174,000) and UD ($172,000). Adding indirect costs totaled DUCB $400,000, UD $376,000 and EUCB conservative $376,000; optimistic $343,000 (Canadian dollars). Rate of GvHD had the largest impact on indirect costs through preventing return to work (lower productivity). The ICER using the direct costs only for EUCB vs UD was $500 (optimistic) to $7300 (conservative) per QALY. When the societal costs are accounted for, EUCB is an economically dominant treatment option. cOnclusiOns: When comparing direct costs EUCB is less expensive for the health care system than DUCB, but more expensive than UD. When comparing overall societal costs including direct and indirect costs EUCB was least expensive, likely due to lower rate of GvHD.
PSY21
Prior auThorizaTioN iN The TreaTmeNT of PaTieNTS WiTh fiBromYalgia or PaiNful diaBeTiC PeriPheral NeuroPaThY
